1. Home
  2. RDACU vs SRPT Comparison

RDACU vs SRPT Comparison

Compare RDACU & SRPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RDACU
  • SRPT
  • Stock Information
  • Founded
  • RDACU N/A
  • SRPT 1980
  • Country
  • RDACU
  • SRPT United States
  • Employees
  • RDACU N/A
  • SRPT N/A
  • Industry
  • RDACU
  • SRPT Biotechnology: Pharmaceutical Preparations
  • Sector
  • RDACU
  • SRPT Health Care
  • Exchange
  • RDACU NYSE
  • SRPT Nasdaq
  • Market Cap
  • RDACU N/A
  • SRPT N/A
  • IPO Year
  • RDACU N/A
  • SRPT 1997
  • Fundamental
  • Price
  • RDACU $10.29
  • SRPT $17.25
  • Analyst Decision
  • RDACU
  • SRPT Buy
  • Analyst Count
  • RDACU 0
  • SRPT 25
  • Target Price
  • RDACU N/A
  • SRPT $64.00
  • AVG Volume (30 Days)
  • RDACU N/A
  • SRPT 7.5M
  • Earning Date
  • RDACU N/A
  • SRPT 08-06-2025
  • Dividend Yield
  • RDACU N/A
  • SRPT N/A
  • EPS Growth
  • RDACU N/A
  • SRPT N/A
  • EPS
  • RDACU N/A
  • SRPT N/A
  • Revenue
  • RDACU N/A
  • SRPT $2,233,371,000.00
  • Revenue This Year
  • RDACU N/A
  • SRPT $26.87
  • Revenue Next Year
  • RDACU N/A
  • SRPT $3.15
  • P/E Ratio
  • RDACU N/A
  • SRPT N/A
  • Revenue Growth
  • RDACU N/A
  • SRPT 59.15
  • 52 Week Low
  • RDACU N/A
  • SRPT $16.96
  • 52 Week High
  • RDACU N/A
  • SRPT $162.95
  • Technical
  • Relative Strength Index (RSI)
  • RDACU N/A
  • SRPT 18.61
  • Support Level
  • RDACU N/A
  • SRPT $18.30
  • Resistance Level
  • RDACU N/A
  • SRPT $22.98
  • Average True Range (ATR)
  • RDACU 0.00
  • SRPT 1.98
  • MACD
  • RDACU 0.00
  • SRPT -1.19
  • Stochastic Oscillator
  • RDACU 0.00
  • SRPT 0.89

About RDACU RISING DRAGON ACQUISITION CORP UNITS 15/11/2028 (1 ORD SHS & 1 RT)

Rising Dragon Acquisition Corp is a blank check company.

About SRPT Sarepta Therapeutics Inc. (DE)

Sarepta Therapeutics Inc is a biotechnology company focused on treating rare, infectious, and other diseases. It targets a broad range of diseases while focusing on the rapid development of its drug candidates. Sarepta's involves proprietary RNA-targeted technology platforms to be used for developing novel pharmaceutical products to treat a broad range of diseases and address key unmet medical needs. The company uses third-party contractors to manufacture its product candidates. Majority of company's product candidates are at an early stage of development.

Share on Social Networks: